Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-36860 IOVANCE BIOTHERAPEUTICS, INC. (Exact name of issuer as specified in its charter) (State or other jurisdiction of (I. ...

1 I OVANCE 1 Corporate Overview March 2022 © 2022, Iovance Biotherapeutics, Inc. Forward-Looking Statements Certain matters discussed in this presentation are "forward-looking statements" of Iovance Biotherapeutics, Inc. (hereinafter referred to as the "Company," "we," "us," or "our") within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). All such written or oral statements made in this presentation, other than statements of historical fact, are forward-looking statements ...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2021 Earnings Conference Call February 24, 2022 4:30 PM ET Company Participants Sara Pellegrino – Vice President, Investor and Public Relations Fred Vogt – Interim President and Chief Executive Officer Igor Bilinsky – Chief Operating Officer Jim Ziegler – Senior Vice President, Commercial Friedrich Finckenstein – Chief Medical Officer Jean-Marc Bellemin – Chief Financial Officer Conference Call Participants Tyler Van Buren – Cowen Michael Yee – Jefferies Peter ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transaction period from __________ to __________ Commission file number: 001-36860 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Del ...

| --- | --- | --- | --- | --- | |-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | 1 Certain matters discussed in this presentation are "forward-looking statements" of Iovance Biotherapeutics, Inc, Inc. (hereinafter referred to as the "Company," "we," "us," or "our") within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). All such written or oral statements made in this presentation, other than statements of historical fact, are forwar ...

| --- | --- | --- | --- | --- | |-------------------------------------------|-------------------------------------------------------------------------|-------------------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | Conference Call & Webcast: Annual Meeting | Clinical Data Highlights at Society for Immunotherapy of Cancer (SITC) | | | | | | | November 13, 2021 | | | | | © 2021, Iovance Biotherapeutics, Inc | | | | 1 Certain matters discussed in this presentation are "forward-looking st ...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q3 2021 Earnings Conference Call November 4, 2021 4:30 PM ET Company Participants Sara Pellegrino – Vice President, Investor Relations & Public Relations Fred Vogt – Interim President and Chief Executive Officer Igor Bilinsky – Chief Operating Officer Jim Ziegler – Senior Vice President, Commercial Friedrich Finckenstein – Chief Medical Officer Jean-Marc Bellemin – Chief Financial Officer Conference Call Participants Mara Goldstein – Mizuho Michael Yee – Jefferies ...

Table of Contents U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-36860 IOVANCE BIOTHERAPEUTICS, INC. (Exact name of issuer as specified in its charter) (State or other jurisdiction of (I.R.S. e ...

Start Time: 16:30 January 1, 0000 5:12 PM ET Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q2 2021 Earnings Conference Call August 05, 2021, 16:30 PM ET Company Participants Frederick Vogt - Interim President and CEO Igor Bilinsky - COO Jim Zigler - SVP, Commercial Friedrich Finckenstein - CMO Jean-Marc Bellemin - CFO Madan Jagasia - SVP of Medical Affairs Sara Pellegrino - VP, Investor and Public Relations Conference Call Participants Michael Yee - Jefferies Mark Breidenbach - Oppenheimer Benjamin Burnett - ...

Table of Contents U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Commission File Number 001-36860 IOVANCE BIOTHERAPEUTICS, INC. (Exact name of issuer as specified in its charter) Delaware 75-3254381 (State or other jurisdiction of (I.R.S. employer incorporation or organization) identification number) 999 Skyway Road, Suite 150, San Carlos, CA 94070 (Address of principal executive offices and zip code) (650) 260-7120 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIE ...